CA2395892C - Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release - Google Patents

Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release Download PDF

Info

Publication number
CA2395892C
CA2395892C CA2395892A CA2395892A CA2395892C CA 2395892 C CA2395892 C CA 2395892C CA 2395892 A CA2395892 A CA 2395892A CA 2395892 A CA2395892 A CA 2395892A CA 2395892 C CA2395892 C CA 2395892C
Authority
CA
Canada
Prior art keywords
peptide
poly
formulation
polymer
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2395892A
Other languages
English (en)
French (fr)
Other versions
CA2395892A1 (en
Inventor
Joachim B. Kohn
Deborah M. Schachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of CA2395892A1 publication Critical patent/CA2395892A1/en
Application granted granted Critical
Publication of CA2395892C publication Critical patent/CA2395892C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2395892A 1999-12-31 2001-01-02 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release Expired - Lifetime CA2395892C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17413399P 1999-12-31 1999-12-31
US60/174,133 1999-12-31
PCT/US2001/000045 WO2001049311A1 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release

Publications (2)

Publication Number Publication Date
CA2395892A1 CA2395892A1 (en) 2001-07-12
CA2395892C true CA2395892C (en) 2014-06-03

Family

ID=22634967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2395892A Expired - Lifetime CA2395892C (en) 1999-12-31 2001-01-02 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release

Country Status (6)

Country Link
US (2) US7326425B2 (https=)
EP (1) EP1251864A4 (https=)
JP (2) JP4917726B2 (https=)
AU (1) AU775905B2 (https=)
CA (1) CA2395892C (https=)
WO (1) WO2001049311A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326425B2 (en) * 1999-12-31 2008-02-05 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
AUPR839001A0 (en) * 2001-10-19 2001-11-15 Eli Lilly And Company Dosage form, device and methods of treatment
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
EP1555278A1 (en) * 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
US8980300B2 (en) 2004-08-05 2015-03-17 Advanced Cardiovascular Systems, Inc. Plasticizers for coating compositions
US7858077B2 (en) * 2005-01-28 2010-12-28 Bezwada Biomedical Llc Functionalized phenolic esters and amides and polymers therefrom
US7691364B2 (en) * 2005-01-28 2010-04-06 Bezwada Biomedical, Llc Functionalized drugs and polymers derived therefrom
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
EP1951260A4 (en) 2005-10-21 2009-11-11 Bezwada Biomedical Llc FUNCTIONALIZED PHENOLIC COMPOUNDS AND POURABLE ARTICLES THEREOF
US8007526B2 (en) 2005-12-01 2011-08-30 Bezwada Biomedical, Llc Difunctionalized aromatic compounds and polymers therefrom
US7935843B2 (en) 2005-12-09 2011-05-03 Bezwada Biomedical, Llc Functionalized diphenolics and absorbable polymers therefrom
EP2114298B1 (en) 2006-02-08 2022-10-19 Medtronic, Inc. Temporarily stiffened mesh prostheses
US8591531B2 (en) 2006-02-08 2013-11-26 Tyrx, Inc. Mesh pouches for implantable medical devices
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
US9028859B2 (en) * 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US20100166854A1 (en) * 2006-10-30 2010-07-01 Rutgers, The State University Of New Jersey Electrospun matrices for delivery of hydrophilic and lipophilic compounds
MX2009004821A (es) 2006-11-06 2009-11-23 Tyrx Pharma Inc Bolsas de malla para dispositivos medicos implantables.
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
AU2008232682B2 (en) 2007-03-29 2013-03-21 Medtronic, Inc. Biodegradable, polymer coverings for breast implants
MX2009011785A (es) * 2007-05-02 2010-03-04 Tyrx Pharma Inc Polimeros de dihidroxibenzoato y usos de los mismos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
US8217134B2 (en) 2007-08-30 2012-07-10 Bezwada Biomedical, Llc Controlled release of biologically active compounds
US8026285B2 (en) * 2007-09-04 2011-09-27 Bezwada Biomedical, Llc Control release of biologically active compounds from multi-armed oligomers
US8048980B2 (en) * 2007-09-17 2011-11-01 Bezwada Biomedical, Llc Hydrolysable linkers and cross-linkers for absorbable polymers
ES2630406T3 (es) 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8652525B2 (en) * 2008-07-10 2014-02-18 Tyrx, Inc. NSAID delivery from polyarylates
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2946770A1 (en) 2008-08-29 2015-11-25 Genzyme Corporation Controlled-released peptide formulations
CA2737769C (en) 2008-09-22 2014-02-04 Medtronic, Inc. Linear polyesteramides from aminophenolic esters
EP2349981A4 (en) * 2008-10-11 2016-11-30 Univ Rutgers BIOKOMPATIBLE POLYMERS FOR MEDICAL DEVICES
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
JP6031033B2 (ja) 2010-08-25 2016-11-24 タイレックス・インコーポレイテッドＴｙｒｘ Ｉｎｃ． 医療デバイスの新規なコーティング
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011326417A1 (en) 2010-11-12 2013-05-09 Tyrx, Inc. Anchorage devices comprising an active pharmaceutical ingredient
JP2012131714A (ja) * 2010-12-20 2012-07-12 Kureha Corp 遅放性バリア材、その製造方法、およびそれを用いた包装容器
AU2012283875B2 (en) 2011-07-20 2016-05-12 Medtronic, Inc. Drug eluting mesh to prevent infection of indwelling transdermal devices
CA2879982C (en) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014137454A1 (en) 2013-03-07 2014-09-12 Tyrx, Inc. Methods and compositions to inhibit the assemblage of microbial cells irreversibly associated with surfaces of medical devices
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
WO2015069305A1 (en) 2013-11-08 2015-05-14 Tyrx, Inc. Antimicrobial compositions and methods for preventing infection in surgical incision sites
WO2017123634A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198507A (en) * 1990-06-12 1993-03-30 Rutgers, The State University Of New Jersey Synthesis of amino acid-derived bioerodible polymers
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5658995A (en) * 1995-11-27 1997-08-19 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
US6120491A (en) * 1997-11-07 2000-09-19 The State University Rutgers Biodegradable, anionic polymers derived from the amino acid L-tyrosine
MXPA99007662A (es) * 1997-02-18 2002-07-22 Univ Rutgers Monomeros derivados de hidroxiacidos, y polimeros preparados a partir de los mismos.
US5912225A (en) * 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
EP1073688B1 (en) 1998-04-13 2015-03-04 Rutgers, The State University The construction of copolymer libraries
EP1263453A4 (en) * 1999-12-31 2008-02-20 Univ Rutgers PHARMACEUTICAL FORMULATION CONSISTING OF A POLYMERMATRIX, FOR REGULATING THE TIME-CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES
US7326425B2 (en) * 1999-12-31 2008-02-05 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release

Also Published As

Publication number Publication date
US20080194469A1 (en) 2008-08-14
JP2012025772A (ja) 2012-02-09
WO2001049311A1 (en) 2001-07-12
JP4917726B2 (ja) 2012-04-18
EP1251864A4 (en) 2006-02-22
AU775905B2 (en) 2004-08-19
US7326425B2 (en) 2008-02-05
JP2003519194A (ja) 2003-06-17
US20030216307A1 (en) 2003-11-20
US8653030B2 (en) 2014-02-18
AU2623701A (en) 2001-07-16
CA2395892A1 (en) 2001-07-12
EP1251864A1 (en) 2002-10-30

Similar Documents

Publication Publication Date Title
CA2395892C (en) Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
US7521061B2 (en) Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
AU784226B2 (en) Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
Anderson et al. Biodegradation and biocompatibility of PLA and PLGA microspheres
Kissel et al. Parenteral depot-systems on the basis of biodegradable polyesters
AU669479B2 (en) Biodegradable polymer blends for delivery of biologically active agent
Eliaz et al. Characterization of a polymeric PLGA‐injectable implant delivery system for the controlled release of proteins
Youxin et al. In-vitro degradation and bovine serum albumin release of the ABA triblock copolymers consisting of poly (L (+) lactic acid), or poly (L (+) lactic acid-co-glycolic acid) A-blocks attached to central polyoxyethylene B-blocks
Bittner et al. Degradation and protein release properties of microspheres prepared from biodegradable poly (lactide-co-glycolide) and ABA triblock copolymers: influence of buffer media on polymer erosion and bovine serum albumin release
Mehta et al. Biodegradable microspheres as depot system for patenteral delivery of peptide drugs
Li et al. Hydrolytic degradation of poly (dl-lactic acid) in the presence of caffeine base
Hanes et al. Degradation of porous poly (anhydride-co-imide) microspheres and implications for controlled macromolecule delivery
Deng et al. In vitro degradation and release profiles for poly-dl-lactide-poly (ethylene glycol) microspheres containing human serum albumin
Li et al. Hydrolytic degradation of coral/poly (DL-lactic acid) bioresorbable material
Schachter et al. A synthetic polymer matrix for the delayed or pulsatile release of water-soluble peptides
Qiao et al. Sustained release of bee venom peptide from biodegradable thermosensitive PLGA-PEG-PLGA triblock copolymer-based hydrogels in vitro
Markland et al. Biodegradable polymers as drug carriers
EP1313454A2 (en) Polymeric compositions and a method of making the same
Gwon et al. New route for synthesizing poly (ethylene glycol)-acrylic acid hydrogels using γ-irradiation for drug delivery carriers
Shi B. Eng., Tianjin University, China, 1987 M. Eng., Tianjin University, China, 1990
Majid The Degradation of the phb and p (hb/hv) Copolymers and Their Uses in Drug Delivery
Shi Development and characterization of Paclitaxel loaded polymeric films based on polysaccharides-graft-poly (E-caprolactone) for the prevention of surgical adhesions
Schachter An evaluation of the drug delivery applications of the tyrosine-derived polyarylates: The development of pulsatile release systems for a model water-soluble peptide
Singh Smart polymer-based controlled-release drug-delivery systems for peptide and protein
Schmitt Hydrolysis and controlled release characteristics of biodegradable poly (esters)

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210104